GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Net Interest Income (for Banks)

PBIGF (Paradigm Biopharmaceuticals) Net Interest Income (for Banks)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Paradigm Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.